Tech Center 1600 • Art Units: 1615
This examiner grants 44% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18029028 | STROKE TREATMENT | Final Rejection | President and Fellows of Harvard College |
| 18453355 | TREATMENT OF SKIN DISORDERS WITH COMPOSITIONS COMPRISING AN EGFR INHIBITOR | Non-Final OA | Sol-Gel Technologies Ltd. |
| 18499534 | PROCESS AND COMPOSITION MATTER OF NANOPARTICLE FORMULATION FOR SYSTEMIC TREATMENT OF SEPSIS | Non-Final OA | Purdue Research Foundation |
| 17819286 | DRY LIPOSOME ADJUVANT-CONTAINING VACCINES AND RELATED METHODS THEREOF | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17923824 | UPCONVERTING NANOPARTICLES | Final Rejection | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 18417805 | COMPOUNDS HAVING SELECTIVE INACTIVATION ACTIVITY | Non-Final OA | THE UNIVERSITY OF TOLEDO |
| 18254912 | METHOD FOR FABRICATING MICROROBOT FOR DELIVERY OF CELL THERAPY PRODUCT AND MICROROBOT ACCORDING THERETO | Non-Final OA | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 17259535 | NON-PESTICIDAL ATTRACT AND KILL COMPOSITION FOR CONTROL OF INSECTS | Non-Final OA | Oregon State University |
| 18675464 | POLYFUNCTIONAL RADICAL SCAVENGER HYDROGEL FORMULATION | Non-Final OA | RXOS Medical Inc. |
| 18675072 | POLYFUNCTIONAL RADICAL SCAVENGER HYDROGEL FORMULATION | Non-Final OA | RXOS Medical Inc. |
| 18559145 | BRAIN-TARGETED ANTIBODY NANOPARTICLE FOR NEURODEGENERATIVE DISEASES THERAPY | Non-Final OA | UNIVERSITY OF SOUTH CAROLINA |
| 18477748 | TRANSLUCENT COSMETIC COMPOSITION | Non-Final OA | Amorepacific Corporation |
| 17707067 | Self-Microemulsifying Multi-Deliverable Systems | Non-Final OA | Quicksilver Scientific, Inc. |
| 18580477 | PHYTOTHERAPEUTIC COMPOSITIONS FOR ENDOTHERAPY | Non-Final OA | NDG NATURAL DEVELOPMENT GROUP S.R.L. |
| 18405569 | Method for Manufacturing a Calcified Tissue Substitute | Non-Final OA | Marine Biomedical Pty Ltd |
| 18245565 | MULTIPARTICULATE DOSAGE FORMS COMPRISING DEUTETRABENAZINE | Non-Final OA | AUSPEX PHARMACEUTICALS, INC. |
| 18567732 | MIXED SOLVENTS FOR SPRAY DRYING FOR PREPARATION OF AMORPHOUS SOLID DISPERSIONS | Non-Final OA | Lonza Bend Inc. |
| 18036676 | ENHANCED FORMULATION STABILIZATION AND IMPROVED LYOPHILIZATION PROCESSES | Final Rejection | BioNTech SE |
| 18037211 | DEVICES, COMPOUNDS AND METHODS FOR INSECT CONTROL | Final Rejection | Agriculture Victoria Services Pty Ltd |
| 18252432 | NON-AQUEOUS GEL COMPOSITION | Final Rejection | Acousia Therapeutics GmbH |
| 18252309 | PEGYLATED RAPAMYCIN COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Final Rejection | SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. |
| 18035923 | Small Molecule Formulation | Final Rejection | Dialectic Therapeutics, Inc. |
| 18022353 | ETOPOSIDE TONIRIBATE FORMULATION | Non-Final OA | CELLACT PHARMA GMBH |
| 17783536 | POWDER FORMULATIONS FOR INHALATION | Non-Final OA | Christian-Albrechts-Universität zu Kiel |
| 18108542 | NANOLIPID CARRIER BASED FORMULATION FOR BRAIN DELIVERY THROUGH INTRANASAL ROUTE AND ITS PREPARATION PROCESS | Final Rejection | AMRITA SCHOOL OF PHARMACY, AMRITA VISHWA VIDYAPEETHAM |
| 17921094 | COMPOSITIONS COMPRISING THYMOL FOR USE IN THE TREATMENT OF INFLAMMATORY OR FUNCTIONAL BOWEL DISORDERS BY MODULATING THE ENDOCANNABINOID SYSTEM | Non-Final OA | VETAGRO INTERNATIONAL S.R.L. |
| 17909279 | PHARMACEUTICAL FORMULATIONS COMPRISING 6-CHLORO-7-(4-(4-CHLOROBENZYL)PIPERAZIN-1 -YL)-2-(1,3-DIMETHYL-1 HPYRAZOL-4-YL)-3H- IMIDAZO[4,5-B]PYRIDINE | Final Rejection | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) |
| 17798014 | PATCH PRODUCT BASED ON NATURAL POLYMERS | Non-Final OA | BAKEL S.R.L. |
| 17866955 | FLEA AND TICK COLLAR | Non-Final OA | Wellmark International |
| 17757455 | SYNOVIAL FLUID SUBSTITUTES | Non-Final OA | Altergon S.A. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy